The association between HIC1 methylation and ovarian cancer: a meta-analysis

Objective: HIC1 is a tumor suppressor gene (TSG) located in the 17p13.3 region that encodes a transcriptional repressor. Research published over the past few years indicates that HIC1 methylation is a critical factor in the oncogenesis of ovarian cancer (OC). However, previous studies had only small sample sizes and thus were unable to reach firm conclusions. Data Sources: Therefore, we performed a meta-analysis to further investigate the association between HIC1 methylation and OC. Studies related to HIC1 methylation and OC were identified from searches of PubMed, EMBASE, Medline and CNKI. Methods of Study Selection: Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the association between the two factors. Subgroup analysis and Begg’s test were used to evaluate heterogeneity and publication bias. From 591 studies, 7 were selected for meta-analysis and these comprised 455 cases and 278 controls. Tabulation, Integration and Results: A significant association between HIC1 methylation and OC was found under the fixed-effects model (OR = 4.306, 95% CI = 2.846 to 6.515). Subgroup analysis of the control type yielded a less tight association (OR = 4.143, p = 0.147, I2 = 41.1%). Finally, we conducted analysis of the Cancer Genome Atlas (TCGA) data and found higher HIC1 methylation levels in OC compared to adjacent non-tumor tissue. Conclusion: In conclusion, this meta-analysis found that HIC1 methylation was strongly associated with OC.

HIC1; Methylation; Ovarian cancer; Meta-analysis; Systematic review

[1] da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz M. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics. 2018; 73: e450s.

[2] Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biology & Medicine. 2017; 14: 9–32.

[3] Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA: A Cancer Journal for Clinicians. 2011; 61: 212–236.

[4] Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Letters. 2014; 342: 257–263.

[5] Cannistra SA. Cancer of the ovary. New England Journal of Medicine. 2004; 351: 2519–2529.

[6] Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients—a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). European Journal of Cancer. 2014; 50: 2090–2098.

[7] Wu Q, Lothe RA, Ahlquist T, Silins I, Tropé CG, Micci F, et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3a1, and CRABP1 as novel targets. Molecular Cancer. 2007; 6: 45.

[8] Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES. RASSF1a promoter methylation in high-grade serous ovarian cancer: a direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA. Oncotarget. 2017; 8: 21429–21443.

[9] Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, et al. Aberrant promoter methylation of sparc in ovarian cancer. Neoplasia. 2009; 11: 126–135.

[10] Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, Turker MS. Genetic alterations distinguish different types of ovarian tumors. International Journal of Cancer. 1995; 64: 434–440.

[11] Markowski J, Sieroń AL, Kasperczyk K, Ciupińska-Kajor M, Auguściak-Duma A, Likus W. Expression of the tumor suppressor gene hypermethylated in cancer 1 in laryngeal carcinoma. Oncology Letters. 2015; 9: 2299–2302.

[12] Law C, Wei L, Tsang FH, Chan CY, Xu IM, Lai RK, et al. HELLS regulates chromatin remodeling and epigenetic silencing of multiple tumor suppressor genes in human hepatocellular carcinoma. Hepatology. 2019; 69: 2013–2030.

[13] Chen C, He B, Chen Y, Lee K, Tung C, Hsu C, et al. HIC1 and RassF1a methylation attenuates tubulin expression and cell stiffness in cancer. International Journal of Molecular Sciences. 2018; 19.

[14] Wang X, Wang Y, Xiao G, Wang J, Zu L, Hao M, et al. Hyperme-thylated in cancer 1 (HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway. Oncotarget. 2016; 7: 30350–30364.

[15] Zhao G, Qin Q, Zhang J, Liu Y, Deng S, Liu L, et al. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer. Annals of Surgical Oncology. 2013; 20: S301–S311.

[16] Wu W, Zhang L, Lin J, Huang H, Shi B, Lin X, et al. Hyper-methylation of the HIC1 promoter and aberrant expression of HIC1/SIRT1 contribute to the development of thyroid papillary carcinoma. Oncotarget. 2016; 7: 84416–84427.

[17] Özdemir İ, Pınarlı FG, Pınarlı FA, Aksakal FNB, Okur A, Uyar Göçün P, et al. Epigenetic silencing of the tumor suppressor genes SPI1, PRDX2, KLF4, DLEC1, and DAPK1 in childhood and adolescent lymphomas. Pediatric Hematology and Oncology. 2018; 35: 131–144.

[18] Tam KF, Liu VWS, Liu SS, Tsang PCK, Cheung ANY, Yip AMW, et al. Methylation profile in benign, borderline and malignant ovarian tumors. Journal of Cancer Research and Clinical Oncology. 2007; 133: 331–341.

[19] Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, Swisher EM, et al. DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecologic Oncology. 2008; 111: 320–329.

[20] Brait M, Maldonado L, Noordhuis MG, Begum S, Loyo M, Poeta ML, et al. Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression. PLoS ONE. 2013; 8: e70878.

[21] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Erratum: global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2020; 70: 313.

[22] Kazanets A, Shorstova T, Hilmi K, Marques M, Witcher M. Epigenetic silencing of tumor suppressor genes: paradigms, puzzles, and potential. Biochimica et Biophysica Acta. 2016; 1865: 275–288.

[23] Dong A, Lu Y, Lu B. Genomic/epigenomic alterations in ovarian carcinoma: translational insight into clinical practice. Journal of Cancer. 2016; 7: 1441–1451.

[24] Gloss BS, Samimi G. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Letters. 2014; 342: 257–263.

[25] Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology. 2012; 56: 994–1003.

[26] Fujii H, Biel MA, Zhou W, Weitzman SA, Baylin SB, Gabrielson E. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene. 1998; 16: 2159–2164.

[27] Eggers H, Steffens S, Grosshennig A, Becker JU, Hennenlotter J, Stenzl A, et al. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma. International Journal of Oncology. 2012; 40: 1650–1658.

[28] Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N. Methylation of tumor suppressor genes in ovarian cancer. Experimental and Therapeutic Medicine. 2012; 4: 1092–1096.